Browse by Medical Category
Accepting New Patients
Dr. Parangi is dedicated to personalized care of your thyroid and parathyroid problems. She has been named to Best of Boston and does surgery on on complex cases of aggressive thyroid cancers, recurrent thyroid cancer, and neck dissections. She makes sure every patient gets state of the art surgical care while receiving the most compassionate care possible, just like she would take care of her own family members. She sees patients at MGH, MGH West and Mount Auburn Hospital.
General & Gastrointestinal Surgery
Go To Programs
Go To Programs
Go To Specialties
Dr. Parangi is a busy endocrine surgeon at Massachusetts General Hospital, Harvard Medical School in Boston. She is dedicated to personalized care of patients with thyroid cancer. She focuses her clinical efforts on endocrine surgery and applies her basic science knowledge and expertise to tumor progression in thyroid cancer. She is one of a handful of thyroid surgeons with expertise in molecular biology and has over 80 publications, many on thyroid cancer therapeutics in premier journals. She has been a council member for the most prestigious organization of endocrine surgeons in the US, The American Association of Endocrine Surgeons, and a member of American Association of Clinical Endocrinologist and The American Thyroid Association. She has won numerous awards for her research on understanding the role of the BRAF oncoprotein, why some patients with thyroid cancer do worse than others and how to help them. Her work in thyroid cancer details certain key genetic changes seen more frequently in those who do poorly, to help elucidate the role of these genetic changes in the aggressive behavior of those cancers. This important research effort focuses on clarifying the molecular mechanism of thyroid cancer invasion and understanding the process of disease progression in patients with thyroid cancer.
View my most recent publications at PubMed
1.Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer.Mekel M, Stephen AE, Gaz RD, Randolph GW, Richer S, Perry ZH, Lubitz CC, Nehs MA, Parangi S, Hodin RA. Am J Surg. 2010 Apr;199(4):485-90.
2.Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms.Lubitz CC, Faquin WC, Yang J, Mekel M, Gaz RD, Parangi S, Randolph GW, Hodin RA, Stephen AE.Thyroid. 2010 Jan;20(1):25-31.
3.A novel orthotopic mouse model of human anaplastic thyroid carcinoma.Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S.Thyroid. 2009 Oct;19(10):1077-84.
4.Thyroid surgery in octogenarians is associated with higher complication rates.Mekel M, Stephen AE, Gaz RD, Perry ZH, Hodin RA, Parangi S.Surgery. 2009 Nov;146(5):913-21.
5.Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J.FASEB J. 2009 Oct;23(10):3368-76. Epub 2009 Jun 15.
Sareh Parangi, MD, endocrine surgeon in the Thyroid Nodule Program at Massachusetts General Hospital, discusses thyroid nodule biopsy results and treatment recommendations.
Back to Top